

Docket No. MWH-0029US

Remarks


This paper is being submitted in response to the Final Office Action dated July 30, 2004, wherein the Examiner rejects claims 1-8, 11, and 13-15 as being unpatentable under either 35 U.S.C. § 102(a), 35 U.S.C. § 102(b), or 35 U.S.C. § 103(a).

In response, and further to a telephone interview with the examiner on October 13, 2004, Applicant has canceled claims 1-18, 11, and 13-15, and has added new claims 30 and 31. Support for these amendments can be found in the specification and claims as originally filed.

Conclusion

Applicant believes that the amendments and remarks contained herein render the captioned application in condition for allowance, and therefore respectfully requests that a Notice of Allowability be forthcoming.

Respectfully submitted,



Matthew M. Catlett
Registration No. 44,067
Genaissance Pharmaceuticals, Inc.
Five Science Park
New Haven, CT 06511
203.773.1450
203.492.4474 (fax)